BDTX vs RLAY
BDTX: A clinical-stage oncology firm using its proprietary MasterKey platform to develop precision, brain-penetrant inhibitors that target families of oncogenic mutations. RLAY: Relay Therapeutics is a precision medicine company leveraging a protein-motion discovery platform to develop targeted therapies for oncology and genetic diseases.
Side-by-side fundamentals
| Metric | BDTX | RLAY | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $2.07 | $18.45 | |
| Market cap | $119M | $4.0B | |
| Net margin FY2025, SEC XBRL | n/a | -1800.6% | |
| Operating margin FY2025, SEC XBRL | n/a | -1971.6% | |
| ROE FY2025, SEC XBRL | +19.9% | -48.8% | BDTX higher |
| ROA FY2025, SEC XBRL | +15.6% | -44.5% | BDTX higher |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +53.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +123.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.63 | 1.78 | |
| 1-year return as of 2026-10-20 close | -49.6% | +158.4% | RLAY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.